Interview with the Executive Chairman: Novocure Ltd. (NASDAQ:NVCR)
William Doyle is the Executive Chairman of Novocure Ltd. (NASDAQ:NVCR). He is also Managing Partner of venture capital investor WFD Ventures LLC. Previously, Mr. Doyle was a member of the Investment Team of Pershing Square Capital, L.P. and an executive of Johnson & Johnson, where he served as a member of Johnson & Johnson’s Consumer Pharmaceuticals and Medical Devices Group Operating Committee, and Vice President, Licensing and Acquisitions. At J&J, he was also Chairman of the Medical Devices Research and Development Council, Worldwide President of Biosense-Webster, and a member of the boards of directors of Cordis and Johnson & Johnson Development Corporation. Earlier in his career, Mr. Doyle was a consultant with McKinsey & Company. He holds a B.S. in materials science and engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School. Profile
TWST: Would you tell us about how and why Novocure got started?
Mr. Doyle: This is one of those really interesting stories. When we think about cancer therapy, we